The effect of empagliflozin on renal outcomes compared to sitagliptin with type 2 diabetes: target trial emulation using electronic medical records
This real-world study suggests that empagliflozin may offer renoprotective benefits compared to sitagliptin in T2D patients. However, the increased serum phosphorus levels warrant careful monitoring. These findings provide valuable insights for clinical decision-making in managing T2D patients at risk of renal complications.
Authors
- Min Ju Kang (ORCID: https://orcid.org/0000-0002-7736-6073)
- Ha Young Jang (ORCID: https://orcid.org/0000-0002-4752-1300)
- Minoh Ko (ORCID: https://orcid.org/0000-0001-9178-8785)
- Jung Mi Oh
- In-Wha Kim
- Hyun Kyung Lee
Institutions
- Gachon University (KR)
- Seoul National University (KR)
- Seoul National University Hospital (KR)
- Daegu Catholic University (KR)
- National University College (PR)
Publication Details
- Journal
- International Journal of Clinical Pharmacy
- Published
- 2025-10-23
- DOI
- https://doi.org/10.1007/s11096-025-02024-9
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 0.00